Tristan Free
speaker
289 appearances
6 recordings
1 series
first heard Jun 2026
last heard 23 Jul
Tristan Free’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 6 in all, peaking in Jun 2026 with 4.
Appearances
And so and do you think that obviously this was was developed for nanobodies, do you think it can be um adapted and used for more complex, larger antibodies?
Uh and would you have any advice for someone who's looking to use your approach?
Um, apply it to a new data set or you know, apply it to their own um uh own sort of drug discovery pipelines?
And and so your your paper's been out for over a year now.
Have you seen any particularly exciting application to this model or have you been able to build on it since uh and use it in in other work?
Fantastic.
Well, it's it's great to get that kind of exclusive on the podcast.
Um yeah.
So thank you so much for joining us on the podcast, Albin.
It's been it's been fascinating to hear such a creative solution to such a widespread problem.
But but also to hear a bit more of a nuanced take on the issue than just throw more data at it.
Um but actually take the time to make sure that data is sort of designed and characterized to fit your purpose.
Um so yeah, thank you so much for coming on the podcast.
Um, if you've enjoyed the podcast and would like to find more like it, you can check out the podcast section of the site on www.biotechniques.com.
You can sign up for our weekly newsletter or follow us on LinkedIn to make sure you never miss an episode.
Thank you for listening and goodbye.
Today we're taking a holistic look at the impact that artificial intelligence and machine learning are having on the design of smart antibodies, the more complex evolution of monoclonal antibodies that can be designed to bind multiple receptors and utilise a number of different mechanisms to elicit a broad range of effects.
You're listening to the Talking Techniques Podcast, and this is the fourth episode of our series covering the ongoing article collection on artificial intelligence and machine learning in adequate development in the journal MABS.
I'm your host, Biotechnique's senior editor, Tristan Free, and today I'm joined by Andrew Buchanan, who, at the time of the publication of his paper,
How to think about designing smart antibodies in the age of Gen AI, integrated biology, technology and experience.
Showing 61–80 of 289 · page 4 of 15
← Previous
Next →